Maternal mortality remains substantially higher for Black women in the United States. Remote monitoring, access, quality-improvement and early-warning approaches are relevant diligence themes, but clinical benefit must be evaluated separately from the disparity statistic.
Disparity / prevalence (static)
2024 maternal mortality: Black women 44.8 vs White women 14.2 deaths per 100,000 live births (~3.2×). Separately, CDC MMRC review of 2017–2019 pregnancy-related deaths found >80% preventable.
Addressable population: 0.85M US women (0.7–1M, 2026)
Source: CDC/NCHS Maternal Mortality Rates in the United States, 2024 (published Mar 2026); CDC Maternal Mortality Review Committees, 2017–2019 preventability analysis
Verified portfolio overlap (Maternal Health, Diagnostics, Wearables) · 23 companies
Alydia HealthMaternal Health · Acquired by Organon (2021)
Medical device company focused on preventing maternal morbidity from postpartum hemorrhage (Jada System)
Verified deal: acquired by Organon (via Merck spinoff) (2021-03-30) — Up to $240M total ($215M upfront cash + $25M contingent milestone); Organon press release Mar 30, 2021
Sources (4)
- Organon.com - press release (Mar 30, 2021)
- Business Wire - Merck acquisition on behalf of Organon spinoff
- Crunchbase - crunchbase.com/organization/alydia-health
- Organon press release - acquisition announcement, 2021
IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
Nest CollaborativeMaternal Health · Private (Seed)
Digital lactation support platform connecting new mothers with IBCLC consultants
No verified acquisition row for this company.
Sources (3)
- Fund portfolio listing (as of 5/31/26)
- Crunchbase - crunchbase.com/organization/nest-collaborative
- Company website - nestcollaborative.com
WillowMaternal Health · Private (Series C)
Wearable breast pump for hands-free pumping
No verified acquisition row for this company.
Sources (4)
- Fund portfolio listing (as of 5/31/26)
- Crunchbase - crunchbase.com/organization/willow-pump
- TechCrunch - breast pump startup coverage, 2021
- Company website - willowpump.com
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
NovocuffMaternal Health · Private (Series A)
Cervical cerclage device to reduce risk of preterm birth
No verified acquisition row for this company.
Sources (3)
- Business Wire - $26M Series A + $2M seed (July 2024)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - novocuff.com
Raydiant OximetryMaternal Health · Private (Series A)
Non-invasive fetal oxygenation monitor for labor and delivery
No verified acquisition row for this company.
Sources (3)
- GlobeNewswire - $7.5M Series A extension (June 2024)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - raydiantoximetry.com
BioReference Health (clinical, women's health, urology and 4Kscore assets)Diagnostics · Select assets under agreement to Labcorp (announced 2026-10-15; pending close)
Select assets of OPKO Health subsidiary BioReference Health under agreement to Labcorp in 2026: laboratory testing businesses focused on clinical and women's health testing, urology and corrections, over 80 patient service centers and the proprietary 4Kscore prostate cancer test; follows BioReference's 2024 sale of clinical diagnostics and reproductive and women's health assets outside NY/NJ to Labcorp (c152)
Verified deal: acquired by LabCorp (2026-10-15) — $722M cash at closing per OPKO 8-K Item 1.01, subject to upward or downward adjustment based on Business revenues at closing; up to $150M additional earnout (total potential $872M). Select-asset purchase (Asset Purchase Agreement dated Oct 14, 2026), not a whole-company acquisition. Pending: subject to HSR clearance; outside date Apr 14, 2027; $28.88M Buyer termination fee on specified regulatory failure. No closedDate until a completion filing or release.
Sources (4)
- SEC EDGAR - OPKO Health 8-K Item 1.01 (Oct 15, 2026; Asset Purchase Agreement dated Oct 14, 2026) https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/opk-20261014.htm
- Labcorp press release via PR Newswire (Oct 15, 2026) https://ir.labcorp.com/news-releases/news-release-details/labcorp-enters-agreement-opko-health-acquire-select-assets
- Labcorp press release via PR Newswire (Mar 28, 2024; About BioReference Health: "Headquartered in Elmwood Park, New Jersey") https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths
- BioReference Health contact page ("Headquarters: 481 Edward H. Ross Drive, Elmwood Park, NJ 07407") https://www.bioreference.com/contact/
BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)Diagnostics · Assets acquired by Labcorp (2024)
BioReference Health laboratory testing business focused on clinical diagnostics and reproductive and women's health in the US outside New York and New Jersey, including patient service centers, customer contracts and operating assets (approximately $100M annual revenue); divested by OPKO Health subsidiary BioReference Health to Labcorp, which excluded oncology, urology and NY/NJ operations
Verified deal: acquired by LabCorp (2024-03-28) — Approximately $237.5M in cash per OPKO 8-K Item 1.01 (agreement) and Item 2.01 (completion), subject to adjustments set forth in the Asset Purchase Agreement dated Mar 27, 2024; no earnout disclosed. Select-asset purchase, not a whole-company acquisition: clinical diagnostics and reproductive and women's health testing outside New York and New Jersey; oncology, urology and all New York and New Jersey operations excluded. Acquired assets generated approximately $100M annual revenue per the Labcorp release.
Sources (4)
- SEC EDGAR - OPKO Health 8-K Item 1.01 (Mar 28, 2024; Asset Purchase Agreement dated Mar 27, 2024) https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm
- SEC EDGAR - OPKO Health 8-K Item 2.01 (Sep 16, 2024; completed) https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm
- Labcorp press release via PR Newswire (Mar 28, 2024; About BioReference Health: "Headquartered in Elmwood Park, New Jersey") https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths
- MedTech Dive (Mar 29, 2024) https://www.medtechdive.com/news/labcorp-buys-bioreference-reproductive-women-health-assets/711713/